Study of the role of VEGF-A and VEGF-A165b in pathophysiology of pulmonary hypertension

Study of the role of VEGF-A and VEGF-A165b in pathophysiology of pulmonary hypertension - Study of the role of VEGF-A and VEGF-A165b in pathophysiology of pulmonary hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032723

Enrollment

Registered

2018-05-31

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary artery hypertension

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients satisfying the criteria for diagnosis of pulmonary hypertension by right heart catheter examination from August 1, 2015 to March 31, 2018, and satisfying the following conditions 1.pulmonary hypertension Group 1:pulmonary arterial pulmonary hypertension(PAH) Group 2:pulmonary hypertension due to left heart disease Group 3:pulmonary hypertension associated with pulmonary disease and/or hypoxia Group 4:Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Group 5:pulmonary hypertension accompanied by unknown multifactorial mechanism 2.Men and women aged 16 years or older 3.WHO function classification 2 or more

Exclusion criteria

Exclusion criteria: Diagnosis of malignant tumor Those already using pulmonary vasodilator (prostaglandin I 2 preparation, endothelin receptor antagonist, phosphodiesterase 5 inhibitor, stimulant of soluble guanylate cyclase)

Design outcomes

Primary

Measure	Time frame
circulating plasma VEGF-A,VEGF-A165b	—

Countries

Japan

Contacts

Public ContactShiro Adachi

Nagoya University Department of Advandced in Cardiopulmonary Disease

bontenyama@med.nagoya-u.ac.jp052-744-0388

Outcome results